RAFAEL HOLDINGS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.71 USD | 0.00% |
|
0.00% | -6.56% |
Financials (USD)
| Sales 2022 | 410K | Sales 2023 | 279K | Capitalization | 48.59M |
|---|---|---|---|---|---|
| Net income 2022 | -125M | Net income 2023 | -1M | EV / Sales 2022 | 90.2 x |
| Net cash position 2022 | 11.54M | Net cash position 2023 | 21.5M | EV / Sales 2023 | 97.1 x |
| P/E ratio 2022 |
-0.32
x | P/E ratio 2023 |
-24.8
x | Employees | 13 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 76.32% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 week | -3.93% | ||
| Current month | -0.58% | ||
| 3 months | -2.84% | ||
| 6 months | +16.33% | ||
| Current year | -6.56% |
1 week
1.65
1.84
1 month
1.651.89
Current year
1.621.95
1 year
1.442.52
3 years
1.4466.44
5 years
1.4466.44
10 years
1.4466.44
| Managers | Title | Age | Since |
|---|---|---|---|
William Conkling
CEO | Chief Executive Officer | 53 | 21-03-14 |
David Polinsky
DFI | Director of Finance/CFO | 53 | 17-11-30 |
Howard Jonas
CHM | Chairman | 68 | 17-08-16 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Howard Jonas
CHM | Chairman | 68 | 17-08-16 |
| Director/Board Member | 80 | 18-03-25 | |
Michael Weiss
BRD | Director/Board Member | 73 | 18-02-28 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 1.71 | 0.00% | 7 625 |
| 24-04-24 | 1.71 | 0.00% | 4,206 |
| 24-04-23 | 1.71 | -1.72% | 8,463 |
| 24-04-22 | 1.74 | -1.14% | 6,981 |
| 24-04-19 | 1.76 | +2.92% | 26,024 |
Delayed Quote Nyse, April 24, 2024 at 04:00 pm EDT
More quotes
Rafael Holdings, Inc. is a holding company with interests in clinical and early-stage pharmaceutical companies. The Company's segments include healthcare and real estate. The Company's investments include Cornerstone Pharmaceuticals, Inc., which is a cancer metabolism-based therapeutics company; LipoMedix Pharmaceuticals Ltd., which is a clinical-stage pharmaceutical company; Barer Institute Inc., which is a preclinical cancer metabolism research operation; Cyclo Therapeutics Inc., which is a clinical-stage biotechnology company dedicated to developing medicines for patients and families living with diseases through its therapeutic asset like Trappsol and Cyclo; Day Three Labs, Inc., which offers pharmaceutical-grade technology like Unlokt, and Rafael Medical Devices, LLC, which is an orthopedic-focused medical device company developing instruments to advance minimally invasive surgeries. Its real estate segment comprises of a portion of a commercial building in Israel.
Calendar
2024-06-10
- Q3 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -6.56% | 42.04M | |
| +31.39% | 28.38B | |
| -14.74% | 26.6B | |
| +23.05% | 26.54B | |
| +41.97% | 23.07B | |
| -6.96% | 23.03B | |
| +2.90% | 19.81B | |
| +26.13% | 16.75B | |
| -6.25% | 16.96B | |
| +18.54% | 14.92B |
- Stock Market
- Equities
- RFL Stock
